Advances in Second-Line Therapies for Non-Small Cell Lung Cancer
Author Information
Author(s): Wang Kinsley, Leyba Alexis, Hsu Robert, Normanno Nicola
Primary Institution: University of Southern California Keck School of Medicine
Hypothesis
What are the current and emerging second-line therapeutic options for advanced or metastatic non-small cell lung cancer (NSCLC)?
Conclusion
The review highlights the need for effective second-line therapies in NSCLC, emphasizing the potential of new treatments and the importance of personalized approaches.
Supporting Evidence
- Lung cancer is the leading cause of cancer mortality globally, with NSCLC accounting for 85% of cases.
- Resistance to first-line treatments is common, creating a significant unmet need for effective second-line therapies.
- Anti-angiogenic drugs combined with chemotherapy have shown moderate success in treating NSCLC.
- Emerging therapies like antibody-drug conjugates and CAR-T cell therapy are being explored for their potential in NSCLC treatment.
- Regular monitoring through techniques like liquid biopsies allows for real-time tracking of mutations.
Takeaway
Lung cancer is really serious, and even though there are some treatments, many people still need better options when their first treatments don't work. This study looks at new ways to help those patients.
Methodology
This is a review article evaluating current and emerging second-line therapeutic options for advanced or metastatic NSCLC.
Potential Biases
Potential bias in the selection of studies reviewed and the interpretation of their results.
Limitations
The review does not provide new clinical trial data but summarizes existing literature.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website